Novartis | NOVN - Beneficio Operativo





Beneficio Operativo Cambio Fecha
AbbVie USD 4.73B 1.08B 2026-03
Alcon AG USD 313M 19M 2025-12
Almirall EUR 30.23M 12.8M 2025-12
Amgen USD 3.83B 130M 2026-03
AstraZeneca USD 7.11B 4.14B 2026-03
Autolus Therapeutics Ltd USD -72.47M 845K 2025-12
Bayer EUR 1.11B 1.65B 2025-12
Biogen USD 514.3M 128.8M 2026-03
Bristol-Myers Squibb USD 4.2B 562M 2025-12
Eli Lilly USD 9.78B 792M 2026-03
Fresenius EUR 713M 139M 2025-12
Fresenius Medical Care EUR 663M 213.06M 2025-12
Galapagos EUR 780.56M 822.23M 2025-12
Genmab DKK 260M 199M 2025-12
Gilead Sciences USD 2.96B 551M 2025-12
GlaxoSmithKline GBP 2.29B 856M 2026-03
GRIFOLS EUR 275.38M 76.74M 2025-12
Hikma Pharmaceutical USD 348M 161M 2025-12
J&J USD 6.62B 1.03B 2026-03
Lonza CHF 673M 243M 2025-06
Merck EUR 474M 738M 2025-12
Merck USD -1.88B 8.12B 2026-03
Novartis USD 4.24B 171M 2026-03
Novartis USD 4.06B 521M 2025-12
Novo Nordisk DKK 32.38B 1.7B 2025-12
Orion EUR 114.8M 213.4M 2026-03
Pfizer USD 4.65B 3.99B 2025-12
Philips EUR 719M 390M 2025-12
Recordati EUR 278.23M 112.58M 2025-12
Regeneron Pharmaceuticals USD 744.8M 153.8M 2026-03
Roche Holding CHF 9.56B 3.8B 2025-12
Sanofi EUR 1.94B 239M 2026-03
UCB EUR 1.29B 571M 2025-12